Neurocrine biosciences presents data on treatment of patients with congenital adrenal hyperplasia at ece 2023

Post hoc analyses of phase 2 study of crinecerfont in adults with cah demonstrate androgen reduction across a broad range of glucocorticoid doses post hoc analyses of phase 3 study demonstrate efmody® (hydrocortisone modified-release hard capsules) reduced androgen levels compared to immediate-release hydrocortisone in patients with cah san diego , may 12, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), a leading neuroscience-focused biopharmaceutical company, today announced that it will present new analyses of phase 2 data of the investigational drug crinecerfont in adults with classic congenital adrenal hyperplasia (cah) due to 21-hydroxylase deficiency (21-ohd) and post hoc analyses of phase 3 data for efmody® (hydrocortisone modified-release hard capsules). efmody is approved by the european commission for the european economic area (including northern ireland) (eea) and by the uk medicines and healthcare products regulatory agency (mhra) for the treatment of adults and adolescents (12 years and older) with cah.
NBIX Ratings Summary
NBIX Quant Ranking